CING News

Cingulate, a Phase 3-ready biotech developing formulations of stimulant drugs for ADHD, raised $25 million by offering 4.2 million units at $6, the low end of the downwardly revised range of $6 to $8. The company offered 0.6 million more units than anticipated. Each unit consists of one share of common stock and one warrant, exercisable at $6. ...read more

Cingulate, a Phase 3-ready biotech developing formulations of stimulant drugs for ADHD, lowered the proposed deal size for its upcoming IPO on Wednesday. In its latest filing, the company also disclosed financials for the 9mo21 and replaced underwriters Oppenheimer & Co., Ladenburg Thalmann, and Brookline Capital Markets with Aegis Capital Corp. and Laidlaw &...read more

Cingulate, a Phase 3-ready biotech developing formulations of stimulant drugs for ADHD, lowered the proposed deal size for its upcoming IPO on Tuesday. The Kansas City, KS-based company now plans to raise $40 million by offering 4.4 million shares at a price range of $8 to $10. The company had previously filed to offer 4.5 million shares at a range of $10 to $12. At the midpoint of...read more

The Fall IPO market is expected to stay busy with eight IPOs schedule to raise $1.9 billion in the week ahead. Software development platform GitLab (GTLB) plans to raise $598 million at a $9.4 billion market cap. This founder-led company provides an end-to-end DevOps platform to accelerate the software development cycle from weeks to minutes and enable rapid,...read more